Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450733 | 1.00 | L3MBTL1 (0.41) | L3MBTL1SLC6A1SLC6A11ACHERAB9A | |
| SCHEMBL23777353 | 0.86 | SLC6A11 (0.48) | SLC6A1SLC6A11ACHEMAPK1MEN1 | |
| SCHEMBL29450730 | 0.80 | LMNA (0.62) | L3MBTL1SLC6A1SLC6A11ACHERAB9A | |
| SCHEMBL25937677 | 0.77 | ALDH1A1 (0.45) | L3MBTL1MAPK1KMT2ASIGMAR1 | |
| SCHEMBL25937667 | 0.77 | ALDH1A1 (0.45) | L3MBTL1MAPK1KMT2ASIGMAR1 | |
| SCHEMBL24294060 | 0.77 | ALDH1A1 (0.45) | L3MBTL1MAPK1KMT2ASIGMAR1 | |
| SCHEMBL30011087 | 0.77 | ALDH1A1 (0.45) | L3MBTL1MAPK1 | |
| SCHEMBL28628138 | 0.76 | SLC6A11 (0.47) | SLC6A1SLC6A11MEN1KMT2A | |
| SCHEMBL30980726 | 0.76 | HDAC1 (0.44) | L3MBTL1MAPK1KMT2A | |
| SCHEMBL25937665 | 0.76 | ALDH1A1 (0.44) | L3MBTL1MAPK1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ERBB2, PCNA, MRE11 | L3MBTL1 623/4885SLC6A1 4189/4885SLC6A11 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.